Clinical Trial Update: Ph II Study of Perifosine Plus Gleevec for Patients With GIST [Phase 2]

View source ↗

Summary

Phase II study evaluating perifosine plus imatinib (Gleevec) in patients with gastrointestinal stromal tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Gleevec (Imatinib)
• Perifosine (perifosine)

Snippet

Sponsor: AEterna Zentaris | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED